TITLE

Legislation may offer long-term solution

PUB. DATE
April 2011
SOURCE
Same-Day Surgery;Apr2011, Vol. 35 Issue 4, p35
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on potential solutions to a growing drug shortage in the U.S. that were discussed at a 2010 drug summit which was sponsored by the American Society of Health-System Pharmacists and other groups and discusses legislation called the Preserving Access to Life-Saving Medications Act, which was proposed by U.S. Senator Amy Klobuchar and U.S. Senator Bob Casey, and may provide a long-term solution to the drug shortage.
ACCESSION #
59699327

 

Related Articles

  • Record high drug shortages warrant FDA policy changes, AHA tells House health panel.  // AHA News;7/11/2011, Vol. 47 Issue 14, p1 

    The article reports on the action of the U.S. Food and Drug Administration to avoid drug shortages, such as the implementation of the Prescription Drug User Fee Act and the Preserving Access to Life Saving Medications Act.

  • FDA May Alter Rules on Drug Combos.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to change rules enabling manufacturers greater leeway in developing drug combinations.

  • FDA Actions.  // CenterWatch Monthly;Nov2015, Vol. 22 Issue 11, p16 

    A chart is presented depicting a sampling of the U.S. Food and Drug Administration (FDA) regulatory actions taken during October 2015.

  • FDA: Most Drugmakers Meet Postmarketing Commitments. Young, Donna // BioWorld Today;11/11/2010, Vol. 21 Issue 219, p1 

    The article reports on an analysis by Booz-Allen-Hamilton (BAH) of 1,551 backlogged postmarketing studies from 1977 to 2007 which showed that most drug and biologic manufacturers required to complete postmarketing studies are meeting their commitments. According to the results, which were...

  • No Strings Attached. Peters, Rita C. // Drug Discovery & Development;May2012, Vol. 15 Issue 5, p4 

    The author discusses the implications of the reauthorization of the Prescription Drug User Fee Act (PDUFA) in the U.S. She explains that the legislation must be renewed before its expiration date on September 30, 2012 because it may compromise the drug review process and may force the Food and...

  • Dueling draft bills address tracking of pharmaceuticals. Traynor, Kate // American Journal of Health-System Pharmacy;6/15/2013, Vol. 70 Issue 12, p1008 

    The article reports on the draft legislation which was released by U.S. Congress in April 2013, which would create federal standards for monitoring pharmaceuticals that are distributed in the market. A federal track-and-trace electronic system for drug distribution will be implemented, according...

  • Policy Watch. Drug shortages challenge the healthcare community, FDA, and pharmaceutical manufacturers. Wechsler, Jill // Formulary;Nov2011, Vol. 46 Issue 11, p503 

    The article reports on increased attention which the U.S. health care system, the White House and the U.S. Congress is giving in 2011 to the problem of drug shortages involving drugs that are used to treat cancer, pain and other serious medical conditions. A discussion of problems which the...

  • New fee structure proposed by FDA might lead to more talk. Waters, Hannah // Nature Medicine;Oct2011, Vol. 17 Issue 10, p1159 

    The article reports that the Prescription Drug User Fee Act (PDUFA) proposed by the U.S. Food and Drug Administration (FDA) will need a number of meetings to finalize and address other concerns. It states that the proposed PDUFA call for mandatory meetings while the drug review process...

  • Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Braun, M. Miles; Farag-El-Massah, Sheiren; Kui Xu; Coté, Timothy R. // Nature Reviews Drug Discovery;Jul2010, Vol. 9 Issue 7, p519 

    The 1983 US Orphan Drug Act has stimulated the development of new therapies for rare diseases. To provide the first comprehensive overview of orphan-designated products and their indications, this article quantitatively analyses the characteristics and distribution of orphan designations and...

  • New drug and biological product approvals, 2010. Traynor, Kate // American Journal of Health-System Pharmacy;2/1/2011, Vol. 68 Issue 3, p186 

    The article presents the drugs which received the marketing approval from the U.S. Food & Drug Administration (FDA). It includes the Tocilizumab or Actemra which is used for treating moderate to severe rheumatoid arthritis, the Pradaxa oral thrombin inhibitor, and the tesamorelin or Egrifta for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics